Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body RadioTherapy and REsection (LINNEARRE-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02433574
Recruitment Status : Recruiting
First Posted : May 5, 2015
Last Update Posted : July 17, 2018
Sponsor:
Information provided by (Responsible Party):
Theo Tsakiridis, M.D., Ph.D., FRCPC, Juravinski Cancer Center

Brief Summary:

Despite improved staging and operative techniques, the rate of incomplete resection (R1) of NSCLC has remained significant over the last decades. Patients with R1 resection have significantly worse survival compared to those with complete resection (R0).

This is a phase I study that investigates the feasibility and safety of delivering Stereotactic Body Radiotherapy (SBRT) to patients with locally invasive NSCLC (cT3-4, N0-1) who are at risk for incomplete resection.

Twenty patients with NSCLC will be treated with SBRT followed by surgery and appropriate adjuvant therapy. Patients will be divided into groups, of 5 patients each, treated with escalating doses (35, 40, 45 and 50 Gy) in 10 daily fractions.

The primary outcome is the feasibility i.e. the ability to complete safely SBRT and surgery (within 6 weeks). Secondary outcomes include acute and late adverse events, R0/R1/R2 rates and secondary surrogates of feasibility.

If successful, this study will lead to further evaluation of pre-operative SBRT in NSCLC.


Condition or disease Intervention/treatment Phase
Non-Small-Cell Lung Cancer Carcinoma Radiation: Neoadjuvant Stereotactic body radiation (SBRT) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study: Locally Invasive NSCLC Treated With NEo-Adjuvant Stereotactic Body Radiotherapy and REsection
Study Start Date : November 2015
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : January 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Neoadjuvant stereotactic body radiation
Single arm study. Four cohorts of 5 patients will undergo neo-adjuvant SBRT for lung cancer. Eligible patients will have operable, borderline resectable lung cancer , they will be treated with SBRT, prior to undergoing surgical resection.
Radiation: Neoadjuvant Stereotactic body radiation (SBRT)

Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.

The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments.





Primary Outcome Measures :
  1. Feasibility of SBRT followed by surgery (proportion of patients who can undergo 10 fractions of SBRT followed by Surgery) [ Time Frame: 18 months ]
    Feasibility of neo-adjuvant SBRT followed by surgery. This will be measured as the proportion of patients who can undergo 10 fractions of SBRT followed by Surgery as scheduled (within 6 weeks from registration).


Secondary Outcome Measures :
  1. Early safety of SBRT-S through collection of serious adverse events (CTCAE version 4.0 grade 3 or higher) from beginning of SBRT to 4 weeks after completion of surgery. [ Time Frame: 18 months ]
  2. Late safety profile of SBRT-S through collection of surgical complication rates assessed at 6 and 18 months post-registration (thus 30 months from opening of the study, assuming it takes 1 year to complete accrual). [ Time Frame: 30 months ]
    Complications recorded include incidence of bronchopleural fistula, esophageal fistula, wound healing complications (dehiscence, infection) and post-operative pulmonary complications).

  3. Secondary feasibility outcomes (including accrual rate, consent rate, rates of deviation from scheduled treatment plan, and reasons for delay) [ Time Frame: 18 months ]
    These include accrual rate, consent rate, rates of deviation from scheduled treatment plan of 6 weeks, and reasons for delay)

  4. Pathological response following neoadjuvant SBRT (proportion of R0, R1 and R2 resections) [ Time Frame: 18 months ]
    To determine the proportion of R0, R1 and R2 resections after neoadjuvant SBRT.

  5. Pathologic changes associated with neo-adjuvant SBRT with analysis of irradiated tissues [ Time Frame: 18 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients will be included if they are aged 18 years or older,
  • with biopsy proven NSCLC,
  • clinically staged T3-T4 marginally resectable i.e. deemed at risk to achieve <R0 resection (such as invasion of critical mediastinal or hilar structures, nodal extra-capsular extension, chest wall, vertebral bodies, compromised bronchial stump margin, based on CT images of the chest).
  • Patients also need to be pathologically staged N0-1 disease,
  • with an SBRT CTV≤200cm3, based on planning CT images.
  • ECOG status is required to be <2 within 4 weeks prior to registration and
  • patients must be deemed medically operable by the surgical team.

Exclusion Criteria:

  • Patients will be excluded if they are deemed medically inoperable by the surgical team
  • and have a weight loss of ≥10% within 3 months prior to pathological diagnosis.
  • Patients will also have no absolute contraindication to RT such as connective tissue disease, pacemaker-dependent patient with the pacemaker receiving higher than tolerance dose, had no had previous RT to the current region of the study, that would result in overlap of RT fields,
  • patients must have no plans to receive other local therapy while on study, except at disease progression,
  • patients have not had other malignancy within 2 years prior to the study (other than non-melanomatous skin cancers)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02433574


Contacts
Layout table for location contacts
Contact: Clinical Trials Department Juravinski Cancer Center 905-387-9495
Contact: Naghmeh Isfahanian, MD 9053879495 isfahanian@hhsc.ca

Locations
Layout table for location information
Canada, Ontario
Juravinski Cancer Centre Recruiting
Hamilton, Ontario, Canada, L8V 5C2
Contact: Theos Tsakiridis, MD PhD    905-308-3574 ext 64704    tsakirid@HHSC.CA   
Sponsors and Collaborators
Juravinski Cancer Center
Investigators
Layout table for investigator information
Principal Investigator: Theodoros Tsakiridis, M.D., Ph.D. Juravinski Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Theo Tsakiridis, M.D., Ph.D., FRCPC, Radiation Oncologist, Associate Professor, Juravinski Cancer Center
ClinicalTrials.gov Identifier: NCT02433574     History of Changes
Other Study ID Numbers: LINNEARRE-I
First Posted: May 5, 2015    Key Record Dates
Last Update Posted: July 17, 2018
Last Verified: July 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Theo Tsakiridis, M.D., Ph.D., FRCPC, Juravinski Cancer Center:
radiosurgery
Neoadjuvant Therapy

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Non-Small-Cell Lung
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases